# CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial

Source: https://onco.cc/key-papers/paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016/  
OnCo record `paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In 405 Cuban patients with advanced lung cancer, the EGF vaccine CIMAvax-EGF after chemotherapy gave a median survival of 10.8 months against 8.9 with supportive care; the difference was significant only by a weighted test and among patients who had at least four doses.

## Summary

Published as "A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients". CIMAvax-EGF is human recombinant epidermal growth factor joined to a carrier protein with the adjuvant Montanide ISA51, intended to make the body produce antibodies that block EGF from reaching its receptor. Four to six weeks after first-line chemotherapy, 405 patients with stage IIIB or IV non-small cell lung cancer were randomised to the vaccine or to best supportive care.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: Clinical Cancer Research
- Year: 2016
- DOI: 10.1158/1078-0432.CCR-15-0855
- Authors: Rodriguez PC, Popa X, Martínez O, et al.
- Findings: Median survival in the safety population was 10.83 months with the vaccine and 8.86 months with supportive care (HR 0.82, P = 0.100 by the standard log rank test; P = 0.04 by a weighted log rank test).; Among patients who received at least four doses, median survival was 12.43 against 9.43 months (HR 0.77, P = 0.036).; Vaccinated patients with high baseline EGF concentration had a median survival of 14.66 months; adverse reactions were mostly grade 1 or 2 injection-site pain, fever, vomiting and headache.
- What it means: The main evidence for Cuba's lung cancer vaccine: well tolerated, with a survival gain that depends on how the analysis is done and that was clearest in patients who completed the induction doses.
- Caveats: The standard primary comparison was not statistically significant.; The per-protocol benefit excludes patients who stopped early, which can favour the vaccine arm.; Control patients received supportive care only, not an active maintenance treatment.

## Sources

- Clin Cancer Res 2016: https://doi.org/10.1158/1078-0432.CCR-15-0855
- PubMed: https://pubmed.ncbi.nlm.nih.gov/26927662/

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [CIMAvax-EGF](https://onco.cc/drugs/cimavax-egf/)
- companies: [CIMAB](https://onco.cc/companies/cimab/)
- institutions: [Instituto Nacional de Oncología y Radiobiología (INOR)](https://onco.cc/institutions/inor-cuba/), [National Coordinating Centre of Clinical Trials, Cuba (CENCEC)](https://onco.cc/institutions/cencec-cuba/)

---
JSON: https://onco.cc/api/v1/entities/paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016.json